Drug and Therapeutics Bulletin 1994;32:60-61; doi:10.1136/dtb.1994.32860
Copyright © 1994 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Lacidipine - a once-daily calcium antagonist for hypertension

Relevant BNF section: 2.6.2

In our recent review of calcium antagonists for the treatment of patients with cardiovascular disease we concluded that most patients could be managed with formulations of one of the original calcium antagonists, verapamil, diltiazem or nifedipine.1 Experience is greatest with these drugs, and none of the newer alternatives appeared more effective or better tolerated. Lacidipine (Motens - Boehringer Ingelheim) is the latest calcium antagonist to be marketed for the treatment of patients with mild to moderate hypertension. It is licensed for once- daily use without the need for a modified-release formulation; in this respect it resembles amlodipine. The manufacturer of lacidipine claims that its gradual onset of action "cushions the fall in blood pressure" and "cushions against side effects".






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1994 BMJ Publishing Group Ltd.